HIV
ViiV Healthcare’s Injectable Formulation Dosed Every Two Months Shows Higher Efficacy than Daily Oral PrEP
GSK
PR-M05-20-NI-034-1543May 22, 2020
HIV Treatment
ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-treatment Regimen Administered Every Two Months
GSK
PR-M08-19-NI-074Aug 26, 2019
FDA Approval
GSK’s ViiV Healthcare Seeks FDA Approval for Combination HIV Therapy
Emilie Branch
Pharma's Almanac
PAO-M10-18-NI-029Oct 29, 2018